

Adult CIRB - Late Phase Emphasis Meeting Agenda

October 1, 2026

I New Study - Initial Review

NRG-BN015, A Randomized Phase 3 Clinical Trial of Postoperative Radiotherapy versus Postoperative Surveillance for Clinical Low-Risk, Molecular High-Risk Meningioma and Longitudinal Surveillance for Clinical and Molecular Low-Risk Meningioma (Version Date 08/26/26)

II Continuing Review

A022101, A Pragmatic Randomized Phase II Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) (Version Date 02/25/26)

III Continuing Review

A062101, A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma (Version Date 07/07/26)

IV Continuing Review

CCTG-BR38, Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients with Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial (Version Date 01/07/26)

V Continuing Review

CCTG-NE1, NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours (Version Date 04/08/26)

VI Continuing Review

CCTG-PR24, Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost in Patients with Unfavourable Risk Localized Prostate Cancer (ASCENDE SBRT) (Version Date 06/27/25)

VII Continuing Review

E3A06, Randomized Phase III Trial of Lenalidomide versus Observation Alone In Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (Version Date 04/30/26)

VIII Continuing Review

EA1211, Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial (Version Date 07/07/25)

IX Continuing Review

EA8191, Phase III Study of Local or Systemic Therapy INTensification DIrected by PET in Prostate Cancer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) (Version Date 03/18/26)

X Continuing Review

NRG-BR007, A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (Version Date 10/20/23)

XI Continuing Review

NRG-GY026, A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive,

Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma (Version
Date 06/18/26)

XII Continuing Review

S1802, Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer (Version Date 06/07/24)

XIII Continuing Review

S2504, A Randomized Phase III Study of PIRtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (pirAMID) (Version Date 02/20/26)

XIV Continuing Review

MM10A-S03, Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy (Version Date 04/13/26)
